Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma

NCT03463057 is registered in ClinicalTrials.gov with Stichting Hemato-Oncologie voor Volwassenen Nederland as lead sponsor.

NCT NCT03463057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03463057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 30, 2018
Completion date
January 31, 2027
Enrollment
109 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl, nhl